News sentiment analysis powered by sentiment-insight.com
Bayer CEO Says Breakup Wouldn’t Fix All of the Company’s Ills | Mint
A stream of negative news has rekindled calls from investors for Bayer to unlock value by spinning off its units. Bayer’s acquisition of Monsanto for $63 billion in 2018 left the company saddled with debt, restricting its ability to make acquisitions.
Bayer CEO Says Breakup Wouldn’t Fix All of the Company’s Ills | Mint Bayer shares have lost 21% of their value since last Friday’s close. The failure of recent drug trials leaves Bayer facing a “patent cliff" where its current product Xarelto, a blood thinner, is due to expire.
Exclusive-Bayer holds call with bond investors after raft of bad news Bayer held a call with investors on Monday after a raft of bad news led some of them to question whether the German group had been upfront about its prospects. The drug-to-pesticides group priced the investment grade bond on Thursday last week, with the deal closing on Tuesday.
Bayer holds call with bond investors after raft of bad... Bayer held a call with investors on Monday after a raft of bad news led some of them to question whether the German group had been upfront about its prospects. The drug-to-pesticides group priced the investment grade bond on Thursday last week, with the deal closing on Tuesday. On Sunday, it was hit by a major drug development setback.
Monsanto ordered to pay additional $165 million to Seattle school employees over PCBs After nearly $870 million in verdicts from alleged PCBs exposure at Sky Valley Education Center, a jury has ordered Bayer’s Monsanto to pay an additional $165 million. The employees claimed that chemicals made by the company leaked from light fixtures and got them sick.
Weed killer company Roundup ordered to pay more than $1.5 billion to three gardeners over claims it... Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California have all been diagnosed with non-Hodgkin's lymphoma. Their lawsuit claimed their illness was related to glyphosate, an active chemical in the product. Their verdict marks the fourth straight legal loss for Bayer - after the agricultural giant was found not liable to plaintiffs in nine consecutive trials.
Weed killer company Roundup ordered to pay more than $1.5 billion to three gardeners over claims it... Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California have all been diagnosed with non-Hodgkin's lymphoma. Their lawsuit claimed that their illness was related to glyphosate, an active chemical in the product owned by Bayer. Their verdict marks the fourth straight legal loss for Bayer - after the agricultural giant was found not liable to plaintiffs in nine consecutive trials.
Bayer CEO says tougher cash outlook will be considered... Bayer's strategic review will consider a potentially tougher outlook for cash flows. German conglomerate suffered a major drug development setback. Group late on Sunday aborted a large late-stage trial testing a new anti-clotting drug.
UPDATE 1-Bayer stops blood thinner drug trial for lack of effect in major setback Germany's Bayer has aborted a large late-stage trial testing a new anti-clotting drug for lack of efficacy. The trial halt marks another setback for company burdened by a weak herbicide business.
European shares listless after robust week; Bayer... European shares listless after robust week; Bayer tumbles to 14-year low. Italian banks stocks gain after Moody's upgrade. Bayer woes pile up as blood thinner drug trial fails. Julius Baer falls after guidance cut.
US STOCKS-Wall St eyes subdued open after recent rally,... Microsoft up as ousted OpenAI CEO set to join company. Bristol Myers Squibb down as Bayer's anti-clotting drug trial fails. Futures: Dow down 0.05%, S&P down 1.02%, Nasdaq up 0.04%.
US STOCKS-Nasdaq leads Wall Street gains as Microsoft... The Nasdaq boasted its highest closing level since July 31. The S&P 500 registered its highest close since Aug. 1. Microsoft rises as ousted OpenAI CEO set to join company. Bristol Myers down as Bayer's anti-clotting drug trial fails.
US STOCKS-Nasdaq futures edge higher as Microsoft shines Microsoft up as ousted OpenAI CEO set to join company. Bristol Myers down as Bayer's anti-clotting drug trial fails. Dow up 0.05%, S&P 500 0.08%, Nasdaq 0.18%.
US STOCKS-Nasdaq leads Wall Street's gains as Microsoft... Microsoft rises as ousted OpenAI CEO set to join company. Bristol Myers down as Bayer's anti-clotting drug trial fails. Dow up 0.55%, S&P 0.70%, Nasdaq 1.05%.
Bayer stops blood thinner drug trial for lack of effect... Germany's Bayer has aborted a large late-stage trial testing a new anti-clotting drug for lack of efficacy. It said in a statement late on Sunday that experimental anticoagulant asundexian was inferior to Bristol-Myers Squibb and Pfizer's Eliquis.
US STOCKS-Nasdaq leads Wall St higher as Microsoft hits... Microsoft up as ousted OpenAI CEO set to join company. Bristol Myers down as Bayer's anti-clotting drug trial fails. Dow up 0.11%, S&P 0.20%, Nasdaq 0.47%.
Markets’ week ahead: European stocks inch up on Japan rally The CAC 40 index was up 0.22% to €7,249.4 on Monday morning. The Stoxx 600 was also slightly up at €455.9, but the FTSE 100 index was down 0.14% to £7,493.42. LVMH, Bayer and TotalEnergies were among the top gainers.
Bayer ordered to pay $1.56 billion in latest US trial... Bayer ordered to pay $1.56 billion in latest US trial loss over Roundup weedkiller. Verdict is the fourth straight loss in court for Bayer, after the company had been found not liable to plaintiffs in nine consecutive trials. Bayer says it has strong arguments to get the recent verdicts overturned on appeal.
Bayer ordered to pay $1.56 billion in latest US trial loss over Roundup weedkiller A Missouri jury ordered Bayer to pay $1.56 billion to four plaintiffs who claimed the company's Roundup weedkiller caused injuries including cancer. The verdict is the fourth straight loss in court for Bayer, after the company had been found not liable to plaintiffs in nine consecutive trials.
Bayer recalls one lot of cancer drug Vitrakvi due to... Bayer recalls one lot of its cancer drug Vitrakvi in the U.S. due to presence of microbial contamination. The company has not received any adverse event reports related to the lot to date. The recalled lot was distributed to wholesalers and specialty pharmacies.
Sign Up
